BR0311759A - Usos de um antagonista do receptor 5 do glutamato metabotrópico ou um sal farmaceuticamente aceitável ou um isÈmero óptico do mesmo e métodos de inibição de relaxamentos transientes do esfìncter esofagiano inferior, de tratamento da doença do refluxo gastro-esofagiano, de prevenção do refluxo, de tratamento ou prevenção da regurgitação, de doença pulmonar, da asma, de laringites crÈnicas e de administração da falta de desenvolvimento - Google Patents

Usos de um antagonista do receptor 5 do glutamato metabotrópico ou um sal farmaceuticamente aceitável ou um isÈmero óptico do mesmo e métodos de inibição de relaxamentos transientes do esfìncter esofagiano inferior, de tratamento da doença do refluxo gastro-esofagiano, de prevenção do refluxo, de tratamento ou prevenção da regurgitação, de doença pulmonar, da asma, de laringites crÈnicas e de administração da falta de desenvolvimento

Info

Publication number
BR0311759A
BR0311759A BR0311759-6A BR0311759A BR0311759A BR 0311759 A BR0311759 A BR 0311759A BR 0311759 A BR0311759 A BR 0311759A BR 0311759 A BR0311759 A BR 0311759A
Authority
BR
Brazil
Prior art keywords
treating
disease
regurgitation
asthma
reflux
Prior art date
Application number
BR0311759-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Anders Lehmann
Jan Mattson
Original Assignee
Astrazeneca Ab
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20288301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0311759(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Nps Pharma Inc filed Critical Astrazeneca Ab
Publication of BR0311759A publication Critical patent/BR0311759A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR0311759-6A 2002-06-20 2003-06-19 Usos de um antagonista do receptor 5 do glutamato metabotrópico ou um sal farmaceuticamente aceitável ou um isÈmero óptico do mesmo e métodos de inibição de relaxamentos transientes do esfìncter esofagiano inferior, de tratamento da doença do refluxo gastro-esofagiano, de prevenção do refluxo, de tratamento ou prevenção da regurgitação, de doença pulmonar, da asma, de laringites crÈnicas e de administração da falta de desenvolvimento BR0311759A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201943A SE0201943D0 (sv) 2002-06-20 2002-06-20 New use
PCT/US2003/016223 WO2004000316A1 (en) 2002-06-20 2003-06-19 Use of mglur5 antagonists for the treatment of gerd

Publications (1)

Publication Number Publication Date
BR0311759A true BR0311759A (pt) 2005-03-08

Family

ID=20288301

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311759-6A BR0311759A (pt) 2002-06-20 2003-06-19 Usos de um antagonista do receptor 5 do glutamato metabotrópico ou um sal farmaceuticamente aceitável ou um isÈmero óptico do mesmo e métodos de inibição de relaxamentos transientes do esfìncter esofagiano inferior, de tratamento da doença do refluxo gastro-esofagiano, de prevenção do refluxo, de tratamento ou prevenção da regurgitação, de doença pulmonar, da asma, de laringites crÈnicas e de administração da falta de desenvolvimento

Country Status (24)

Country Link
EP (1) EP1513525B1 (enExample)
JP (2) JP4683920B2 (enExample)
CN (1) CN100430056C (enExample)
AT (1) ATE395059T1 (enExample)
AU (1) AU2003241585B2 (enExample)
BR (1) BR0311759A (enExample)
CA (1) CA2489730C (enExample)
CY (1) CY1107954T1 (enExample)
DE (1) DE60320990D1 (enExample)
DK (1) DK1513525T3 (enExample)
ES (1) ES2304510T3 (enExample)
IL (1) IL165138A0 (enExample)
IS (1) IS7654A (enExample)
MX (1) MXPA04012659A (enExample)
NO (1) NO20050154L (enExample)
NZ (1) NZ536559A (enExample)
PL (1) PL372186A1 (enExample)
PT (1) PT1513525E (enExample)
RU (1) RU2324484C2 (enExample)
SE (1) SE0201943D0 (enExample)
SI (1) SI1513525T1 (enExample)
UA (1) UA81627C2 (enExample)
WO (1) WO2004000316A1 (enExample)
ZA (1) ZA200409908B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
WO2005060971A1 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
WO2005060961A2 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
WO2005077368A2 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
AU2005214378A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
EP1716130A1 (en) * 2004-02-18 2006-11-02 AstraZeneca AB Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
JP5249919B2 (ja) * 2006-03-29 2013-07-31 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕＲ２アンタゴニストとしてのピリジン及びピリミジン誘導体
EP2272509A1 (en) 2006-09-11 2011-01-12 Novartis AG New Uses of metabotropic glutamate receptors
JP2008245225A (ja) * 2007-03-29 2008-10-09 Kddi Corp 波長パス経路決定装置、波長パス設定制御システム及びプログラム
WO2009024491A1 (en) * 2007-08-20 2009-02-26 F. Hoffmann-La Roche Ag Use of mglur5 antagonists for the treatment of gerd
MX2010014222A (es) 2008-06-30 2011-03-29 Novartis Ag Star Combinaciones que comprenden moduladores de mglur para el tratamiento de enfermedad de parkinson.
JP2012533601A (ja) 2009-07-23 2012-12-27 ノバルティス アーゲー 運動失調症の処置または予防のための、アザビシクロアルキル誘導体またはピロリジン−２−オン誘導体の使用
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
EP2490691A1 (en) 2009-10-20 2012-08-29 Novartis AG Use of 1h-quinazoline-2,4-diones
RU2013103001A (ru) 2010-06-24 2014-07-27 Новартис Аг Применение 1н-хиназолин-2,4-дионов
US20140171448A1 (en) 2011-01-27 2014-06-19 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
MX2014002693A (es) 2011-09-07 2014-06-04 Novartis Ag Uso de 1h-quinazolina-2,4-dionas para usarse en la prevencion o el tratamiento de epilepsia fotosensible.
CA2898043C (en) 2013-01-15 2019-08-06 Novartis Ag Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy
KR101879919B1 (ko) 2013-01-15 2018-07-18 노파르티스 아게 알파 7 니코틴성 아세틸콜린 수용체 작용물질의 용도
US20220387410A1 (en) * 2019-11-05 2022-12-08 Claes Thulin 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of surmenage in a mammal

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0250572A1 (en) * 1986-01-03 1988-01-07 The University Of Melbourne Gastro-oesophageal reflux composition
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
AU758955C (en) * 1998-05-15 2004-09-30 Cancer Advances, Inc. Method for the treatment of gastroesophageal reflux disease
RU2144331C1 (ru) * 1998-11-05 2000-01-20 Московский НИИ уха, горла и носа Способ лечения хронического гиперпластического ларингита
CN1313465C (zh) * 1999-08-19 2007-05-02 Nps药物有限公司 杂多环化合物及其用于制备代谢性谷氨酸受体拮抗剂的应用
IL155163A0 (en) * 2000-10-02 2003-10-31 Janssen Pharmaceutica Nv Metabotropic glutamate receptor antagonists

Also Published As

Publication number Publication date
ES2304510T3 (es) 2008-10-16
ATE395059T1 (de) 2008-05-15
CN1662235A (zh) 2005-08-31
NZ536559A (en) 2007-08-31
AU2003241585B2 (en) 2009-06-25
EP1513525A1 (en) 2005-03-16
JP2011068669A (ja) 2011-04-07
RU2005101411A (ru) 2005-07-10
SI1513525T1 (sl) 2008-08-31
PL372186A1 (en) 2005-07-11
CA2489730C (en) 2011-11-22
CY1107954T1 (el) 2013-09-04
AU2003241585A1 (en) 2004-01-06
ZA200409908B (en) 2006-08-30
CN100430056C (zh) 2008-11-05
DK1513525T3 (da) 2008-08-11
RU2324484C2 (ru) 2008-05-20
JP4683920B2 (ja) 2011-05-18
DE60320990D1 (de) 2008-06-26
IS7654A (is) 2005-01-19
WO2004000316A1 (en) 2003-12-31
PT1513525E (pt) 2008-06-24
HK1075833A1 (en) 2005-12-30
NO20050154L (no) 2005-01-11
IL165138A0 (en) 2005-12-18
EP1513525B1 (en) 2008-05-14
JP2006507225A (ja) 2006-03-02
UA81627C2 (ru) 2008-01-25
SE0201943D0 (sv) 2002-06-20
MXPA04012659A (es) 2006-05-25
CA2489730A1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
SE0201943D0 (sv) New use
EA200801806A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
CY1106697T1 (el) Ν-υποκατεστημενες υδρομορφονες και η χρηση αυτων
BRPI0513565A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir uma atividade de proteìna cinase, e para tratar um paciente tendo uma condição que é mediada por atividade de proteìna cinase, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
CY1106645T1 (el) Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
MXPA05010958A (es) Derivados indazol como inhibidores jnk.
BR0317600A (pt) ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina
BR0214112A (pt) Indazolilpirrolotriazinas modificadas c-5
BRPI0509298A (pt) composto, composição farmacêutica, métodos de inibir receptor h3 de histamina em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, obesidade, e um distúrbio ou doença, e, uso de um composto
CY1106927T1 (el) Φαρμακευτικη συνθεση ενος pde4 ή pde3/4 αναστολεα και ανταγωνιστη υποδοχεα ισταμινης
BR0012175A (pt) Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca
BR0115936A (pt) 2-anilino-benzimidazóis substituìdos e sua aplicação como inibidores de nhe
EP4599894A3 (en) Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
PT1336407E (pt) Composicao contendo um antagonista do receptor de angiotensina e um diuretico e sua utilizacao para o tratamento da hipertensao
CY1106365T1 (el) Συνδυασμος ενος αναστολεα pde και ενος ανταγωνιστη υποδοχεων λευκοτριενιου
SE9902267D0 (sv) New compounds
TW200604165A (en) Novel benzyl(idene)-lactam derivatives
WO2004026837A3 (en) Histamine h3 receptor antagonists, preparaton and therapeutic uses
ATE445396T1 (de) 3-arylthioindol-2-carbonsäureamidderivate und ihre analoge als hemmer von caseinkinase i
WO2006114666A8 (en) SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES
BR0307266A (pt) Compostos que inibem a atividade do fator xa
CA2447465A1 (en) Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine for the treatment of pain
DK1503764T3 (da) 5-HT4-receptor-antagonister til behandling af hjertesvigt

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: ASTRAZENECA AB (SE) , NPS PHARMACEUTICALS, INC. (U

Free format text: SEDE DO 2O TITULAR ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070160629/RJ DE 13/11/2007.

B25A Requested transfer of rights approved

Owner name: ASTRAZENECA AB (SE)

Free format text: TRANSFERIDO DE: NPS PHARMACEUTICALS, INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A., E 8A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 7A E 8A ANUIDADES.